Goldman Sachs
DRTS icon

Goldman Sachs’s Alpha Tau Medical DRTS Stock Holding History

Goldman Sachs’s Portfolio DRTS Stock Details DRTS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-26,189
Closed -$185K – 6675
2026
Q1 		$185K Buy
+26,189
New +$185K ﹤0.01% 6106
2025
Q4 		– Sell
-12,315
Closed -$55.5K – 6522
2025
Q3 		$55.5K Buy
+12,315
New +$41.9K ﹤0.01% 6163

Other funds holding DRTS

GIA
Gem Investment Advisors Teaneck, New Jersey $163M AUM
HighTower Advisors
HighTower Advisors Chicago, Illinois $104B AUM 28.3% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.6B AUM 109.3% 1-Year Est. Return
AF
Aquamarine Financial George Town $1.81B AUM 38.21% 1-Year Est. Return
PC
Pier Capital Stamford, Connecticut $755M AUM 94.38% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
AC
Apella Capital West Hartford, Connecticut $7.08B AUM 17.38% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
Polen Capital Management
Polen Capital Management Boca Raton, Florida $11.6B AUM 8.03% 1-Year Est. Return
Focus Partners Wealth
Focus Partners Wealth Boston, Massachusetts $97.6B AUM 29.43% 1-Year Est. Return

Goldman Sachs's DRTS Position: Q2 2026 in Review

Goldman Sachs sold out of Alpha Tau Medical (DRTS) in Q2 2026, closing a stake of 26,189 shares — an estimated $185K sold.

Goldman Sachs first reported a position in DRTS in Q3 2025 and held it in 2 quarters. The position peaked at $185K in Q1 2026. 74 funds tracked by Wall St. Rank hold DRTS as of Q2 2026.

  • Goldman Sachs reported no remaining Alpha Tau Medical position as of Q2 2026 after selling out during the quarter.
  • Goldman Sachs sold 26,189 Alpha Tau Medical shares in Q2 2026, an estimated $185K.
  • Goldman Sachs first reported a position in Alpha Tau Medical in Q3 2025 and held it in 2 quarters.
  • Goldman Sachs's Alpha Tau Medical position peaked at $185K in Q1 2026.
  • 74 funds tracked by Wall St. Rank held Alpha Tau Medical as of Q2 2026.

Based on Goldman Sachs's 13F filing for Q2 2026, filed 14 Aug 2026.